Symbiotec Pharmalab Demands P/E of 58 Amid API Dominance
The story in brief
Symbiotec Pharmalab, the only company with a presence across the top 10 corticosteroid and steroidal-hormone APIs in FY26, demands a P/E multiple of up to 58 based on its post-IPO equity and net profit. APIs account for over 96% of revenue, with new initiatives like complex injectables and CDMO offerings contributing the rest. The company operates two API facilities and has expanded fermentation capacity to 700 KL.